{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:12:06Z","timestamp":1789683126946,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001704","name":"ESCMID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018955","name":"Leeds Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.cmi.2025.01.028","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T12:09:59Z","timestamp":1738066199000},"page":"1011-1017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Antimicrobial susceptibility testing of Clostridioides difficile: a dual-site study of three different media and three therapeutic antimicrobials"],"prefix":"10.1016","volume":"31","author":[{"given":"Jane","family":"Freeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid M.J.G.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Harmanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma V.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiep Klaas","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.01.028_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.20","article-title":"Clostridium difficile infection","volume":"2","author":"Smits","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.cmi.2025.01.028_bib2","doi-asserted-by":"crossref","first-page":"651.e1","DOI":"10.1016\/j.cmi.2022.12.019","article-title":"Clostridioides difficile infection (CDI): a pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI)","volume":"29","author":"Wingen-Heimann","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.01.028_bib3","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","article-title":"Trends in U.S. burden of Clostridioides difficile infection and outcomes","volume":"382","author":"Guh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.01.028_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-72799-8_1","article-title":"Economic burden of Clostridium difficile infection in European countries","volume":"1050","author":"Reigadas Ram\u00edrez","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.cmi.2025.01.028_bib5","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1056\/NEJMoa1408913","article-title":"Burden of Clostridium difficile infection in the United States","volume":"372","author":"Lessa","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.cmi.2025.01.028_bib6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.01.028_bib7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/ciab718","article-title":"Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.028_bib8","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/cid\/ciaa484","article-title":"Impact of revised infectious diseases society of America and society for healthcare epidemiology of America clinical practice guidelines on the treatment of Clostridium difficile infections in the United States","volume":"72","author":"Clancy","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.028_bib9","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1093\/jac\/dkab231","article-title":"Mechanisms of antibiotic resistance of Clostridioides difficile","volume":"76","author":"Wickramage","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.01.028_bib10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13756-020-00815-5","article-title":"Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis","volume":"9","author":"Sholeh","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.cmi.2025.01.028_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.diagmicrobio.2015.05.015","article-title":"A national survey of the molecular epidemiology of Clostridium difficile in Israel: the dissemination of the ribotype 027 strain with reduced susceptibility to vancomycin and metronidazole","volume":"83","author":"Adler","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.028_bib12","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41467-020-14382-1","article-title":"Plasmid-mediated metronidazole resistance in Clostridioides difficile","volume":"11","author":"Boekhoud","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2025.01.028_bib14","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/jac\/dkab097","article-title":"Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficile","volume":"76","author":"Boekhoud","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.01.028_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00585-21","article-title":"The Integrity of heme is essential for reproducible detection of metronidazole-resistant Clostridioides difficile by agar dilution susceptibility tests","volume":"59","author":"Wu","year":"2021","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2025.01.028_bib27","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1038\/s41467-023-39429-x","article-title":"Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficile","volume":"14","author":"Olaitan","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2025.01.028_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab365","article-title":"Reduced susceptibility to metronidazole is associated with initial clinical failure in Clostridioides difficile infection","volume":"8","author":"Gonzales-Luna","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.028_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/cid\/ciae087","article-title":"Reduced vancomycin susceptibility in Clostridioides difficile is associated with lower rates of initial cure and sustained clinical response","volume":"79","author":"Eubank","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.028_bib16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10096-019-03708-7","article-title":"Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study","volume":"39","author":"Freeman","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.028_bib19","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2022.27.26.2100704","article-title":"A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from combatting bacterial resistance in Europe CDI (COMBACTE-CDI), July to November 2018","volume":"27","author":"Viprey","year":"2022","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2025.01.028_bib20","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/jac\/dkad194","article-title":"In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile","volume":"78","author":"Marchandin","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.01.028_bib21","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/antibiotics12030435","article-title":"Non-toxigenic Clostridioides difficile Strain E4 (NTCD-E4) prevents establishment of primary C. difficile Infection by epidemic PCR ribotype 027 in an in vitro human gut model","volume":"12","author":"Etifa","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2025.01.028_bib22","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1046\/j.1469-0691.2000.00142.x","article-title":"EUCAST Definitive Document E.DEF 3.1, June 2000: determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution","volume":"6","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.01.028_bib23","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1091\/mbc.E20-09-0583","article-title":"SuperPlotsOfData\u2014a web app for the transparent display and quantitative comparison of continuous data from different conditions","volume":"32","author":"Goedhart","year":"2021","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.cmi.2025.01.028_bib24","article-title":"Eulerr: area-proportional euler and venn diagrams with ellipses","author":"Larsson","year":"2021","journal-title":"R Package Version"},{"key":"10.1016\/j.cmi.2025.01.028_bib25","doi-asserted-by":"crossref","first-page":"1695.e1","DOI":"10.1016\/j.cmi.2021.03.028","article-title":"Development of a EUCAST disk diffusion method for the susceptibility testing of rapidly growing anaerobic bacteria using fastidious anaerobe agar (FAA): a development study using Bacteroides species","volume":"27","author":"Bavelaar","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.01.028_bib26","doi-asserted-by":"crossref","first-page":"795.e1","DOI":"10.1016\/j.cmi.2023.01.027","article-title":"The European committee on antimicrobial susceptibility testing disc diffusion susceptibility testing method for frequently isolated anaerobic bacteria","volume":"29","author":"Matuschek","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.01.028_bib28","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/j.gastro.2020.10.046","article-title":"Plasmid acquisition alters vancomycin susceptibility in Clostridioides difficile","volume":"160","author":"Pu","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2025.01.028_bib29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/cid\/ciaa912","article-title":"Emergence of clinical Clostridioides difficile isolates with decreased susceptibility to vancomycin","volume":"74","author":"Darkoh","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.028_bib30","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/cid\/ciac375","article-title":"Are vancomycin non-susceptible Clostridioides difficile strains emerging?","volume":"75","author":"Lutgring","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.01.028_bib31","series-title":"ESCMID global","article-title":"O0430\u2014emergence of new concerning ribotype of Clostridioides difficile (955)","author":"Puleston","year":"2024"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25000369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25000369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:11:57Z","timestamp":1762366317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25000369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1198743X25000369"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.01.028","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial susceptibility testing of Clostridioides difficile: a dual-site study of three different media and three therapeutic antimicrobials","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.01.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}